Archive for November, 2011
Nigeria: FG and Cost of Cancer Screening
Last Updated on Monday, 28 November 2011 02:03 Written by admin Monday, 28 November 2011 02:03
THE Federal Government’s recent directive to its hospitals to reduce the cost of cancer screening, though very commendable, is long overdue, considering that late diagnosis of the disease has resulted in the high rate of cancer related deaths in the country.
Cancer is one of the leading causes of deaths in the world, especially in developing countries, which carry about 80 per cent of the burden, globally. Unfortunately, in Nigeria with over 160 million people, going by the latest global report on population, detection of the killer non-communicable disease (NCD) is usually late.
Minister of Health, Prof. Onyebuchi Chukwu, who announced the reduction in the cost of screening for breast, cervical, prostate and colon cancers during the recent 17th Annual Conference of the Nigerian Association of Urological Surgeons (NAUS) in Abuja, said the directive to provide screening services at affordable prices is to ensure that the disease is detected early.
Other measures being taken by government to tackle the cancer scourge, he said, include equipping fully the University of Port Harcourt Teaching Hospital, the Federal Medical Centre, Gusau, Zamfara State and the Vesico Virginal Fistula (VVF) Centre, Abakaliki, Ebonyi State with mammography machines, cryoprobes, video culposcopes, ultrasound, loop electrosurgical excision procedure and enzyme-linked immunosorbent assay machines, so that these institutions can serve as referral centres for those who screen positive for pre-malignant lesions.
With the World Health Organisation (WHO) projecting that about 84 million people may die of cancer by 2015 if urgent steps are not taken to arrest the scourge, there is, indeed, need to facilitate a national policy on cancer management, starting with free or significantly reduced cost of cancer screening.
These moves by the Federal Government are steps in the right direction, considering that cancer is one disease that is no respecter of social status and one that has continued to deal devastating blows on the productive segments of the nation’s economy.
Among notable Nigerians whose lives were cut short by cancer are human rights activist and lawyer, Chief Gani Fawehinmi, who died in 2009 after a prolonged battle with lung cancer, Dr. Bekolari Ransome-Kuti, a medical doctor and human rights activist and Yemi Tella, coach of the Nigerian 2007 FIFA U-17 World Cup winning team.
Maryam, wife of former military president, Gen. Ibrahim Babangida, died of ovarian cancer on December 27, 2009 at California’s City Hope Hospital in the United States, aged 61, while the wife of Edo State Governor, Adams Oshiomhole, was swept away by cancer of the breast.
Presently, about two million cancer cases are said to be recorded in Nigeria with an estimated 350,000 new cases being diagnosed annually. Of the two million, only 10 per cent or about 200,000, have access to hospitals with radiotherapy facilities, while out of the number, only five per cent, about 10,000, have the resources to go abroad where they pay between $10,000 and $15,000 per patient for a three to five-weeks course of radiotherapy.
While about 27 per cent of the two million cases are suffering from breast cancer, about 25 per cent are cancer of the cervix cases. And of these two cancers that are devastating women in Nigeria, one has good prognosis, if detected early, while the other can be prevented. Yet they continue to cause untold hardships and deaths simply because of the dearth, and high cost, of facilities, especially for early detection, among other constraints.
Nigeria’s mortality and morbidity statistics for cancer are said to be high due to the late presentation syndrome involving 83-87 per cent of cancer patients, simply because the awareness level of Nigerians, especially women, is very low, even as this is dogged by superstition and cultural restraints.
As a matter of fact, some medical experts have argued that even the estimated 350,000 new cases of cancer diagnosed annually in Nigeria is far from the true figure of the cancer crisis in the country, insisting that a large number of cancers are not detected as majority of Nigerians are poor and live in rural areas, far removed from health facilities.
Lack of, or inadequate, research into this debilitating disease is also a major challenge. Nigeria, for instance, is said to contribute little or nothing to the global body of literature on cancers and most of these contributions are hospital based, perhaps representing the tip of the iceberg as majority of Nigerians live in rural areas, unable to access any health facilities.
As such, the cancer awareness efforts and screening methods to enhance early detection do not seem to have had much impact on the nation.
No doubt, the problems of lack of access to quality health care, ignorance, poverty and poor co-ordination of issues of health education complicate issues. For instance, facilities such as computerised tomography (CT) and Magnetic Resonance Imaging (MRI) are difficult to come by, and when available, the cost of accessing such facilities put them out of reach of the average citizen.
Of more concern is the fact that clinical services for cancer are grossly inadequate and poorly distributed. Only a few centers have functioning radiotherapy equipment, and though radiologic services are said to be generally available, access is seriously limited by high cost.
So, while the Federal Government’s move to reduce the cost of cancer screening in federal hospitals is commended, we call on the authorities to ensure that the screening equipment are available and more easily accessible, especially in the rural areas, while a more vigorous and better co-ordinated effort into cancer research must be encouraged in institutions across the country.
Source: http://allafrica.com/stories/201111241060.html
Posted under Africa, Cancer Research, Compound Screening, Genetics & Pharmacogenetics, HT Screening, Medicinal Chemistry, Oncology Research, Press Releases, R & D, Reports | Comments Off
NMR Fine-Tuned for High-Content Metabolomics Screening
Last Updated on Monday, 28 November 2011 01:48 Written by admin Monday, 28 November 2011 01:48
Scientists report on the development of a nuclear magnetic resonance (NMR)-based method forscreening the metabolomic response of drug-treated mammalian cells to drug therapy. TheSanford-Burnham Medical Research Institute, and Rady Children’s Hospital investigators, say the highly sensitive, fast, and simple method is carried out in 96-well format, and could have particular utility as a method for high-throughput primary screens. The preparation technique takes just five minutes to metabolically inactivate and lyse hundreds of drug-treated samples, and a metabolomic screening of around 100 samples can be carried out in 24 hours.
Giovanni Paternostro, M.D., and colleagues describe their approach, analyze the results of validation studies on drug-treated cancer cell lines, and evaluate the technique for screening a kinase inhibitor library. Their work is described in Nature Communications in a paper titled “Metabolomic high-content nuclear magnetic resonance-based drug screening of a kinase inhibitor library.”
High-throughput screening (HTS) is widely used as a tool in drug discovery, but most screens monitor a single variable, which is often related to activity on a single target, the researchers explain. Although high-content screening (HCS) approaches that provide multivariate readouts are gaining ground, these techniques generally rely on automated digital microscopy.
The technique developed by the Sanford-Burnham researchers involves seeding cells into a 96-well plate and treating them with several drugs. The cells’ metabolism is then quenched using sodium dodecyl sulphate (SDS), and the cells lysed using ultrasonication, in an overall process that takes just five minutes. The entire content of the well, including endo- and exo-metabolome, is then transferred into an NMR tube for analysis.
The team needed to address the relative contribution of the intracellular metabolome to the NMR spectrum acquired on the well content, including both medium and the lysed cell metabolomes. To answer this they generated NMR spectra on the entire content of the well (i.e., both endo- and exo-metabolomes), and also on the exometabolome, the endometabolome, and the medium. They found that major NMR signals arose from the extracellular metabolites, but several signals arising from the intracellular metabolites were also detected, for example glutamate, choline, and phosphocholine. Importantly, they found that spectra acquired on samples containing both endo- and extracellular metabolomes included signals resulting exclusively from the endometabolome—such as phosphocholine and glycerophosphocholine—which didn’t overlap with other extracellular resonances.
The researchers evaluated the sensitivity of the approach for monitoring metabolic changes induced by 24 hours of drug treatment, on both suspension (CCRF-CEM human leukemia cells) and adherent mammalian carcinoma cell lines (human SKOV-3 ovarian cancer cells). The cell lines were treated using either dexamethasone (Dex), rapamycin (Rap) dichloroacetate (DCA), vincristine (Vin), and different doses of L-asparaginase. The resulting spectra, generated using three different 1H NMR pulse sequences, showed that, as expected, the response to drug treatment by the more resistant SKOV-3 cells was far less pronounced compared with the CCRF-CEM cells. Encouragingly, the NMR screening approach could also be applied to detecting metabolic changes in response to forms of intervention, such as the transfection of HeLa cells the microRNAs mir-121 and mir-16. These results indicated that mir-16 induced a greater degree of metabolomic change than mir-121.
Because the developed technique requires just a small amount of cells, the investigators suggest in might have utility in studying drug response directly in primary cells, and so avoid phenotypic changes that can be induced by growth in culture. They evaluated metabolomic changes in cells isolated from bone marrow specimens of an untreated AML patient, in response to treatment with Rap and L-asparaginase, at different doses. In order to specifically highlight metabolic changes in the cells themselves, the NRM spectra acquired on unconditioned medium were compared to those acquired on AML primary cells with and without drug administraton. The resulting spectra clearly showed distinct changes in the metabolome of the primary cells as a result of drug treatment. Further analyses indicated these changes were more pronounced in response to L-asparaginase than for Rap therapy.
The team then moved on to use the approach for carrying out screening of metabolomic response to a kinase inhibitor (KI) library. Multiple rounds of screening on KIs with well-characterized and less well-characterized effects on the metabolome confirmed the utility of the technique for identifying metabolic alterations resulting from inhibitor treatment. More specifically, four hits were validated from their action on the well-characterized lactate to pyruvate ratio parameter.
“We believe that this NMR-based assay might find an immediate relevant application for screening a large number of individual or combinatorial drug interventions, reducing the number of possible drugs to be studied in more detail,” the authors state. “In addition, it might find an immediate relevant application into clinical studies.”
They admit that the main drawback of NMR is the relatively limited number of compounds that can be detected. However, they stress, “although not comprehensive of all metabolites, the wealth of information obtained from the multivariate metabolic readout is of great advantage for drug screening purposes.” The method could therefore represent a valuable high-throughput primary screen, which could then be followed by secondary assays to analyze the exo- and endo-metabolomes of selected hits using combinations of different anaytical platforms.
“There are many other possible applications of this method, for example lactate production and substrate utilization in cancer versus noncancer cells, or gluconeogenesis from different substrates in hepatocytes, relevant to diabetes. Importantly, because the measurements are performed within a global metabolic profile, they can also provide a series of compounds with partially different mechanisms of actions, which can be explored for potential synergies.”
Source: http://www.genengnews.com/gen-news-highlights/nmr-fine-tuned-for-high-content-metabolomics-screening/81245988/
Posted under Compound Screening, HT Screening, North America, Press Releases, Research Projects, USA and Canada | Comments Off
Research at A&M and Scripps finds HIV-killing compound
Last Updated on Monday, 28 November 2011 01:35 Written by admin Monday, 28 November 2011 01:35
COLLEGE STATION - A powerful topical preventative for HIV, the virus that causes AIDS, could be a step closer to clinical trials, thanks to a newly discovered molecular compound that research at Texas A&M University and the Scripps Research Institute shows dissolves the virus on contact.
The ability of the synthetic compound known as “PD 404,182″ to break apart the AIDS-causing virus before it can infect cells was discovered by Zhilei Chen, assistant professor in the university’s Artie McFerrin Department of Chemical Engineering, and her team of researchers. Their findings appear in the November online edition of “Antimicrobial Agents and Chemotherapy,” a journal of the American Society for Microbiology.
“This is a virucidal small-molecule compound, meaning that it has the ability to kill a virus; in this case that virus is HIV,” Chen says.
“Basically, it acts by breaking the virus open. We found that when HIV comes in contact with this compound, it breaks open and loses its genetic material. In a sense, the virus ‘dissolves,’ and its RNA becomes exposed.
Since RNA is pretty unstable, once it is exposed it’s gone very quickly and the virus is rendered non-infectious.”
In other words, the compound works by quickly ripping open the virus before it can inject its genetic material into a human cell. What’s more – and perhaps even more important – the compound, Chen explains, achieves this by acting on something within the virus other than its viral envelope protein, meaning that the virus can’t alter its proteins to bolster its resistance – something that’s made HIV notoriously difficult to treat.
“We believe this compound is not working on the viral protein of the viruses but on something else common in all the viruses on which we tested it – some cellular material common in these viruses,” Chen notes. “Because this compound is acting on a component that is not encoded by the virus, it will be difficult for the virus to evolve resistance against this compound.”
While not a cure for HIV, the compound demonstrates significant potential for use as a preventative, specifically in the form of a topical gel that could be applied in the vaginal canal, Chen explains.
“We conducted a number of tests to demonstrate that this compound remains active in vaginal fluid and is not rendered ineffective,” Chen says. “In the form of a vaginal gel, the compound would serve as a barrier, acting almost instantaneously to destroy the virus before it could infect a cell, thereby preventing HIV transmission from one person to another.”
Surprisingly, Chen and her team did not set out to discover an HIV preventative. Instead, they were conducting screenings of molecules for use in potential drug therapies targeting hepatitis C virus, which causes the dangerous and often fatal disease of the liver. Employing a screening system developed by Chen, the team screened thousands of molecular compounds, in search of those that could block aspects of the HCV life cycle.
During the course of the screenings, the team made an interesting discovery
- not only was PD 404,182 an HCV inhibitor, it also worked on lentiviruses (the group’s negative control in its experimental procedures). Intrigued by that finding, Chen then tested PD 404,182 on HIV, which itself is a lentivirus and found the compound to be even more effective on HIV than on HCV.
“We believe PD 404,182 acts through a unique and important mechanism,” Chen notes. “Most of the known virucidal compounds interact with the virus membrane, but our compound does not appear to interact with the virus membrane. Instead, it bypasses interaction with the membrane and still compromises the structural integrity of the virus.”
The ability of the compound to avoid interaction with the virus membrane is important because human cells have similar membranes, Chen notes. If the compound were to disrupt the structure of the virus membrane, it could also disrupt and ultimately kill human cells. PD 404,182 doesn’t interact with these membranes and is therefore a more attractive option for clinical treatment, Chen says.
As is the case with any potential pharmaceutical, several key steps are still needed before it winds up on drug store shelves. In addition to several rounds of animal studies to ensure the compound is safe for humans, further collaborations with chemists are needed to continue to improve the efficiency of the compound. Chen says. What’s more, Chen also plans to further explore the mechanism by which PD 404,182 breaks apart HIV.
This work is collaboration between Chen’s team, consisting of graduate students Ana Maria Chamoun and Rudo Simeon, postdoctoral associate Karuppiah Chockalingam, and Professor Philippe Gallay’s team at the Scripps Research Institute.
Source: http://www.kxxv.com/story/16095021/research-at-am-and-scripps-finds-hiv-killing-compound
Posted under Cell Analysis, Discoveries, Innovations and Patents, DNA Reasearch, HIV Research, New Drugs, North America, R & D, Reports, Research Projects, USA and Canada | Comments Off
Ancient Chinese cures translate into modern Western medicines
Last Updated on Monday, 28 November 2011 05:52 Written by Editor Monday, 28 November 2011 10:45
The Chem-TCM is the most comprehensive database of its kind and translates more than 12,000 chemicals from more than 300 Chinese herbs used in traditional Chinese medicine (TCM) into Western terminology.
“Future researchers will now be able to better understand the chemical basis of remedies that have been in use for thousands of years,” says David Barlow of King’s College London (KCL), who has helped to develop the database.
TCM chemicals are rarely used as raw materials to develop Western drugs because their complex nature makes the registration process difficult.
The database may also answer one of TCM’s regulatory challenges in the United Kingdom. An EU directive came into effect in the UK this May that makes it illegal for individual practitioners to sell TCM over the counter, except for varieties registered with the UK drug safety watchdog, the Medicines and Healthcare Products Agency.
Posted under Asia, Natural Products, New Products, North America, Press Releases | Comments Off
First Clinical Trial of Autologous Cardiac Stem Cells Shows Positive Results
Last Updated on Tuesday, 22 November 2011 03:13 Written by admin Tuesday, 22 November 2011 03:13
Initial data from the first ever trial to evaluate autologous cardiac stem cell (CSC) transplants in humans suggests that the treatment improves left ventricular (LV) systolic function by an average of 12% over one year, and reduces infarct size in patients with severe heart failure due to ischemic heart disease. The trial investigators say the results triple the 4% average improvement that they had projected and calls for the start of larger Phase II trials.
Stage A of the ongoing open-label Phase I SCIPIO (Stem Cell Infusion in Patients with Ischemic cardiOmyopathy) study, by investigators at the University of Louisville and Brigham and Women’s Hospital, is evaluating CSC transplantation in patients with severe heart failure secondary to ischemic cardiomyopathy. The target population includes patients who underwent coronary artery bypass grafting (CABG), had LV ejection fraction (EF) of less than or equal to 40%, and a previous myocardial infarction.
Treated patients were administered with about a million autologous CSCs by intracoronary infusion, at a mean of 113 days after CABG. To generate the cardiac stem cells, tissue from the right atrial appendage was harvested from the patients at the time of CABG, and CSCs were isolated and expanded at the Brigham and Women’s Hospital.
Data from 14 of 16 patients assigned to the treatment group, and seven from the control group (best supportive care), have now been published in The Lancet to coincide with data presentation at the American Heart Association’s Scientific Sessions meeting in Orlando, FL. The reported data showed that autologous CSC transplantation led to an increase in LVEF from 30.3% before CSC infusion to 38.5% at four months after infusion. In contrast, the LVEF of seven control patients didn’t change over eight months. The benefits of CSC transplantation was even more pronounced at one year in eight evaluated patients, for whom LVEF increased by 12.3 ejection fraction units compared with baseline. In the seven treated patients evaluated using MRI, infarct size was also shown to have decreased by 24% at 4 months, and 30% at one year.
The trial has been led by Roberto Bolli, M.D., at the University of Louisville and Piero Anversa, Ph.D., at Brigham and Women’s Hospital/Harvard Medical School in Boston. “The results are striking,” Dr. Bolli states. “While we do not yet know why the improvement occurs, we have no doubt now that ejection fraction increased and scarring decreased. If these results hold up in future studies, I believe this could be the biggest revolution in cardiovascular medicine in my lifetime.”
The published paper in The Lancet is titled “Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised Phase I trial.”
Source: http://www.genengnews.com/gen-news-highlights/first-clinical-trial-of-autologous-cardiac-stem-cells-shows-positive-results/81245949/
Posted under Cell Analysis, Discoveries, Innovations and Patents, Genetics & Pharmacogenetics, New Drugs, R & D, Reports, Research Projects, Stem Cell Research | Comments Off
FDA Clears Abbott’s Confirmatory Chagas Disease Assay
Last Updated on Tuesday, 22 November 2011 03:11 Written by admin Tuesday, 22 November 2011 03:10
FDA approved Abbott’s in vitro enzyme strip assay for Chagas disease. The Abbott ESA Chagastest detects antibodies to the causative pathogen Trypanosoma cruzi in serum or plasma samples. It is indicated for use as an additional, more specific test on human samples that have been found to be repeatedly reactive using a licensed screening test.
The T. cruzi parasite is transmitted through contact with the feces of an infected triatomine bug, but infection can also occur congenitally, through transfusions of contaminated blood products, or through an organ transplant from an infected donor.
U.S. Centers for Disease Control and Prevention (CDC) estimates suggest that as many as 11 million people worldwide are infected with Chagas disease, including over 300,000 in the U.S. alone. Concerns about Chagas disease transmission through blood led FDA to implement mandatory Chagas disease screening of donated blood back in 2007. “The new Abbott ESA Chagas test provides organizations that screen blood with an approved testing method help the blood supply safe and enable them to confidently counsel infected donors,” remarks John Coulter, divisional vp for Abbott’s diagnostics business.
Source: http://www.genengnews.com/gen-news-highlights/fda-clears-abbott-s-confirmatory-chagas-disease-assay/81245981/
Posted under Cell Analysis, DNA Reasearch, FDA News, Genetics & Pharmacogenetics, R & D, Reports | Comments Off
Chemie Uzbekistan 2011
Last Updated on Tuesday, 15 November 2011 02:29 Written by admin Monday, 14 November 2011 02:18
The 5th Anniversary Central Asian International exhibition «Chemical industry – Chemie Uzbekistan» and the 2nd Uzbek International exhibition of plastics and rubber – «Plastex Uzbekistan 2011» will be held from the 16th till the 18th of November 2011, at the Pavilion 1 of OJSS «Uzexpocentre».
“ITE UZBEKISTAN” is the organizer of the exhibitions
The exhibitions will feature the following sections:
- Agrochemistry
- Raw and equipment for chemical industry
- Composite materials, glass-fibre plastics
- Grit-tipped blade
- Synthetic rubbers
- Household chemicals
- Keeping and transporting of chemical product
- Chemical technologies, research activities
- Laboratory and analytical equipment, devices
- Technic and equipment for producing plastics and rubbers
- Equipment for primary processing materials
- Reprocessing equipment
- Extruders and extrusion utilities
- Machines for ?????? ??? blown forming
- Machines and equipments for producing tyres
- Auxiliary equipment, forms, matrix
- Raw and auxiliary materials
- Mechanical packer
- Semi-finished product and ready-made goods
- Services in the sphere of producing fibers and rubbers
New technologies and innovations in the sphere of chemical substance, raw and auxiliary equipments will be presented at the exhibitions as well.
Such companies from Austria, Germany, India, China, Poland, Russia, Taiwan, Uzbekistan as: Asian diamond classic; Oybek otchopar plastik; Korting Gmbh; Nigmatjon-rin; Omsk plant of trumpet isolation; Xinjiang huangjin mid-asia engineering technology co., Ltd; Uzkimyosanoat; Tongling nextool; Tingdao plastic; Qingdao leader; Trade and Investment Promotion Department of the Embassy of the Republic of Poland in the Rebublic pf Uzbekistan; King hsing; Coperion Gmbh; Starlinger; Lohia starlinger; Shurtan g
Posted under Agriculture Research, Asia, Asia, Equipment & Supplies, Reagents | Comments Off
Vaccine for ovarian, breast cancer shows promise
Last Updated on Wednesday, 9 November 2011 02:40 Written by admin Wednesday, 9 November 2011 02:40
(CBS) A new vaccine that targets ovarian and breast cancer has shown promise in early studies, giving scientists hope they may be closer to stopping the deadly diseases.
PICTURES: 25 breast cancer myths busted
Known as PANVAC, the vaccine triggers the immune system to attack tumor cells.
“With this vaccine, we can clearly generate immune responses that lead to clinical responses in some patients,” lead scientist Dr. James Gulley, director and deputy chief of the clinical trials group at the laboratory of tumor immunology and biology at the National Cancer Institute, said in a written statement.
For their research, published in the Nov. 8 issue of Clinical Cancer Research, scientists tested the vaccine on 26 patients, 12 of whom had breast cancer, 14 of whom ovarian. Most of the women had undergone prior chemotherapy treatment.
What did the scientists find? The vaccine caused women with breast cancer’s disease progression to stall for 2.5 months, and their median survival was 14 months. Four had stable disease, meaning the cancer didn’t grow nor shrink. Women with ovarian cancer reported a two month gap in disease progression, and survived for 15 months, and three had stable disease.
The cancer vaccine stalls cancer progression for only a couple of months? What’s the big deal?
“That time frame is not anything to write home about,” Gulley told WebMD. But he said that one of the women who had breast cancer currently shows evidence of cancer after undergoing the experimental vaccine – four years later.
“It gives us encouragement that we may be on to something here,” he said.
That 32-year-old woman was the youngest in the study, according to WebMD, but her cancer had spread to her liver and chest lymphnodes. At 18 months, there was no X-ray evidence of cancer. Gulley isn’t sure why her treatment was so successful, but the woman had only undergone chemotherapy once. That suggests her immune system might have been stronger than the other women’s.
But don’t expect the vaccine on the market anytime soon. This was only a small study, so more needs to be done.
Gulley said interest in a cancer vaccine is increasing among scientists, but said in the statement that “more studies in the appropriate patient populations are required” to ensure safety, and which patients would benefit most.
The National Cancer Institute has more on cancer vaccines in development.
Source: http://www.cbsnews.com/8301-504763_162-57321522-10391704/vaccine-for-ovarian-breast-cancer-shows-promise/
Posted under Cell Analysis, Discoveries, Innovations and Patents, Medicinal Chemistry, New Drugs, New Products, North America, R & D, Reports, USA and Canada | Comments Off
Main Menu
- Home
- About Bioscreening.net
- Glossary
- Biotechnology Glossary A-I
- Biotechnology Glossary J-Q
- Biotechnology Glossary R-Z
- Bird Flu
- Cheminformatic Glossary
- Endotoxins
- Fullerenes
- Genipin
- Gossypol (Gossipol)
- Grants, Venture Capital, and Government Funding
- High-throughput screening
- Lipinski Rule-of-Five
- Mumie
- Natural Medicine
- Rule-of-Three (Ro3)
- Targeted Libraries
- Web Directory